PURPOSE: To determine the role of radiofrequency ablation (RFA) in patients with inoperable symptomatic recurrent thyroid cancers. MATERIALS AND METHODS: Eleven patients with 16 symptomatic recurrent thyroid cancers but ineligible for surgery were prospectively enrolled and underwent ultrasound-guided RFA with local anesthesia in 16 sessions. The mean tumor volume and diameter were 9 ml (range 0.1-34 ml) and 2.9 cm (range 0.7-4.8 cm), respectively. Patients had dysphagia, hoarseness, dyspnea, or a protruding mass due to recurrent tumors. Tumor volume was calculated from follow-up ultrasound, and symptoms were assessed after RFA. RESULTS: Of 16 sessions, tumor ablation was complete in 6, incomplete in 9, and failed in 1. Incomplete or failed ablation was due to intolerable pain, severe calcified lesion, or tumor encasement of major vessels. Of 15 treated lesions, 13 decreased in volume. Regrowth of treated tumors was observed in 2 lesions. The mean volume reduction was 50.9% (range -9.4 to 96.8%). There were gains for symptom relief for 7 patients (63.6%) with protruding masses (n = 6) and discomfort due to tracheal compression (n = 1). The mean follow-up was 6 months (1-14 months). There were no major complications except a patient with skin burn. CONCLUSION: RFA is feasible and safe, and can improve symptoms in the short term.
PURPOSE: To determine the role of radiofrequency ablation (RFA) in patients with inoperable symptomatic recurrent thyroid cancers. MATERIALS AND METHODS: Eleven patients with 16 symptomatic recurrent thyroid cancers but ineligible for surgery were prospectively enrolled and underwent ultrasound-guided RFA with local anesthesia in 16 sessions. The mean tumor volume and diameter were 9 ml (range 0.1-34 ml) and 2.9 cm (range 0.7-4.8 cm), respectively. Patients had dysphagia, hoarseness, dyspnea, or a protruding mass due to recurrent tumors. Tumor volume was calculated from follow-up ultrasound, and symptoms were assessed after RFA. RESULTS: Of 16 sessions, tumor ablation was complete in 6, incomplete in 9, and failed in 1. Incomplete or failed ablation was due to intolerable pain, severe calcified lesion, or tumor encasement of major vessels. Of 15 treated lesions, 13 decreased in volume. Regrowth of treated tumors was observed in 2 lesions. The mean volume reduction was 50.9% (range -9.4 to 96.8%). There were gains for symptom relief for 7 patients (63.6%) with protruding masses (n = 6) and discomfort due to tracheal compression (n = 1). The mean follow-up was 6 months (1-14 months). There were no major complications except a patient with skin burn. CONCLUSION: RFA is feasible and safe, and can improve symptoms in the short term.
Authors: Antonio Barile; Simone Quarchioni; Federico Bruno; Anna Maria Ierardi; Francesco Arrigoni; Aldo Victor Giordano; Sergio Carducci; Marco Varrassi; Giampaolo Carrafiello; Ferdinando Caranci; Alessandra Splendiani; Ernesto Di Cesare; Carlo Masciocchi Journal: Gland Surg Date: 2018-04
Authors: Yang Guang; Yukun Luo; Yan Zhang; Mingbo Zhang; Nan Li; Ying Zhang; Jie Tang Journal: J Cancer Res Clin Oncol Date: 2017-03-24 Impact factor: 4.553
Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky Journal: Thyroid Date: 2016-01 Impact factor: 6.568
Authors: Giovanni Mauri; Laszlo Hegedüs; Steven Bandula; Roberto Luigi Cazzato; Agnieszka Czarniecka; Oliver Dudeck; Laura Fugazzola; Romana Netea-Maier; Gilles Russ; Göran Wallin; Enrico Papini Journal: Eur Thyroid J Date: 2021-05-25